{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:39:23Z","timestamp":1792784363041,"version":"4.5.0"},"reference-count":315,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Abbott Hellas SA"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.pharmthera.2014.03.003","type":"journal-article","created":{"date-parts":[[2014,3,13]],"date-time":"2014-03-13T20:01:04Z","timestamp":1394740864000},"page":"225-245","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":589,"title":["Azithromycin: Mechanisms of action and their relevance for clinical applications"],"prefix":"10.1016","volume":"143","author":[{"given":"Michael J.","family":"Parnham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesna Erakovic","family":"Haber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos J.","family":"Giamarellos-Bourboulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianpaolo","family":"Perletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert M.","family":"Verleden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2014.03.003_bb0005","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1093\/jac\/dkr190","article-title":"European Surveillance of Antimicrobial Consumption (ESAC): systemic antiviral use in Europe","volume":"66","author":"Adriaenssens","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0010","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1203\/PDR.0b013e318142582d","article-title":"Azithromycin suppresses activation of nuclear factor-kappa B and synthesis of pro-inflammatory cytokines in tracheal aspirate cells from premature infants","volume":"62","author":"Aghai","year":"2007","journal-title":"Pediatr Res"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0015","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMoa1104623","article-title":"Azithromycin for prevention of exacerbations of COPD","volume":"365","author":"Albert","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0020","series-title":"Macrolide antibiotics","first-page":"261","article-title":"Effects of macrolide antibiotics on ribosome function","author":"Allen","year":"2002"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0025","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jama.2013.1937","article-title":"Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial","volume":"309","author":"Altenburg","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0030","doi-asserted-by":"crossref","first-page":"159354","DOI":"10.1155\/2012\/159354","article-title":"Macrolides in chronic inflammatory skin disorders","volume":"2012","author":"Alzolibani","year":"2012","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0035","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1465-9921-14-52","article-title":"Anti-inflammatory effects of clarithromycin in ventilator-induced lung injury","volume":"14","author":"Amado-Rodriguez","year":"2013","journal-title":"Respir Res"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0040","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jpeds.2012.06.067","article-title":"Comparative effectiveness of empiric beta-lactam monotherapy and beta-lactam-macrolide combination therapy in children hospitalized with community-acquired pneumonia","volume":"161","author":"Ambroggio","year":"2012","journal-title":"J Pediatr"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0045","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1177\/106002809502900913","article-title":"Macrolides versus azalides: a drug interaction update","volume":"29","author":"Amsden","year":"1995","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0050","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0149-2918(96)80179-2","article-title":"Erythromycin, clarithromycin, and azithromycin: are the differences real?","volume":"18","author":"Amsden","year":"1996","journal-title":"Clin Ther"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2014.03.003_bb0055","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/S0924-8579(01)00410-1","article-title":"Advanced-generation macrolides: tissue-directed antibiotics","volume":"18","author":"Amsden","year":"2001","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0060","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/jac\/dkh519","article-title":"Anti-inflammatory effects of macrolides\u2014an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?","volume":"55","author":"Amsden","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0065","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.rmed.2008.06.005","article-title":"Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis","volume":"102","author":"Anwar","year":"2008","journal-title":"Respir Med"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0070","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ejphar.2010.06.056","article-title":"Azithromycin inhibits nontypeable Haemophilus influenzae-induced MUC5AC expression and secretion via inhibition of activator protein-1 in human airway epithelial cells","volume":"644","author":"Araki","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0075","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1469-0691.2012.03783.x","article-title":"Impact of guideline-concordant antibiotics and macrolide\/beta-lactam combinations in 3203 patients hospitalized with pneumonia: prospective cohort study","volume":"19","author":"Asadi","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0080","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/cid\/cis414","article-title":"Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis","volume":"55","author":"Asadi","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0085","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ejphar.2003.11.035","article-title":"Azithromycin reverses anticancer drug resistance and modifies hepatobiliary excretion of doxorubicin in rats","volume":"484","author":"Asakura","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0090","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1128\/AAC.50.5.1805-1812.2006","article-title":"Novel effects of azithromycin on tight junction proteins in human airway epithelia","volume":"50","author":"Asgrimsson","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0095","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ijantimicag.2010.11.037","article-title":"Clarithromycin modulates immune responses in experimental peritonitis","volume":"37","author":"Atmatzidis","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0100","first-page":"2597","article-title":"Degradative transport of cationic amphiphilic drugs across phospholipid bilayers","volume":"364","author":"Baciu","year":"2006","journal-title":"Philos Transact A Math Phys Eng Sci"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0105","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2230.2006.02322.x","article-title":"The effect of azithromycin on reactive oxygen species in rosacea","volume":"32","author":"Bakar","year":"2007","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0110","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2310\/6650.2007.00011","article-title":"Azithromycin protects against hyperoxic lung injury in neonatal rats","volume":"55","author":"Ballard","year":"2007","journal-title":"J Investig Med"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0115","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/00044011-199815020-00009","article-title":"Pharmacokinetics of oral azithromycin in serum, urine, polymorphonuclear leucocytes and inflammatory vs non-inflammatory skin blisters in healthy volunteers","volume":"15","author":"Ballow","year":"1998","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0120","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.phrs.2012.06.011","article-title":"Anti-inflammatory mechanism of action of azithromycin in LPS-stimulated J774A.1 cells","volume":"66","author":"Banjanac","year":"2012","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0125","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s10787-012-0165-1","article-title":"Antibacterial and immunomodulatory properties of azithromycin treatment implications for periodontitis","volume":"21","author":"Bartold","year":"2013","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0130","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1378\/chest.08-3056","article-title":"Azithromycin attenuates airway inflammation in a noninfectious mouse model of allergic asthma","volume":"136","author":"Beigelman","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0135","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1465-9921-11-90","article-title":"Azithromycin attenuates airway inflammation in a mouse model of viral bronchiolitis","volume":"11","author":"Beigelman","year":"2010","journal-title":"Respir Res"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0140","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3855\/jidc.18","article-title":"Macrolides for the treatment of severe respiratory illness caused by novel H1N1 swine influenza viral strains","volume":"3","author":"Bermejo-Martin","year":"2009","journal-title":"J Infect Dev Ctries"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0145","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1164\/rccm.201307-1200OC","article-title":"Epidemiology of nontuberculous mycobacterial infections and associated chronic macrolide use among persons with cystic fibrosis","volume":"188","author":"Binder","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0150","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.pupt.2009.12.002","article-title":"Long-term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy","volume":"23","author":"Blasi","year":"2010","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0155","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1517\/13543784.11.2.189","article-title":"The macrolides","volume":"11","author":"Blondeau","year":"2002","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0160","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1053\/j.ajkd.2003.10.027","article-title":"Necrotizing glomerulonephritis caused by Bartonella henselae endocarditis","volume":"43","author":"Bookman","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0165","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1001\/jama.2011.1829","article-title":"Immunosuppression in patients who die of sepsis and multiple organ failure","volume":"306","author":"Boomer","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0170","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1124\/jpet.109.155838","article-title":"Azithromycin and clarithromycin inhibit lipopolysaccharide-induced murine pulmonary neutrophilia mainly through effects on macrophage-derived granulocyte\u2013macrophage colony-stimulating factor and interleukin-1beta","volume":"331","author":"Bosnar","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0175","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.intimp.2010.12.010","article-title":"Azithromycin inhibits macrophage interleukin-1beta production through inhibition of activator protein-1 in lipopolysaccharide-induced murine pulmonary neutrophilia","volume":"11","author":"Bosnar","year":"2011","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0180","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1128\/AAC.49.6.2372-2377.2005","article-title":"Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin","volume":"49","author":"Bosnar","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0185","doi-asserted-by":"crossref","first-page":"6111","DOI":"10.1021\/jm300356u","article-title":"N\u2032-substituted-2\u2032-O,3\u2032-N-carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity","volume":"55","author":"Bosnar","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0190","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1080\/00365540512331336622","article-title":"Intermittent azithromycin treatment for respiratory symptoms in patients with chronic Chlamydia pneumoniae infection","volume":"36","author":"Branden","year":"2004","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0195","unstructured":"Bright, G.M. & Hauske, J.R. (1984). Azahomoerythromycin D derivative and intermediates thereof. US Patent 4,465,674 A."},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0200","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1111\/bph.12077","article-title":"The antibiotic azithromycin is a motilin receptor agonist in human stomach: comparison with erythromycin","volume":"168","author":"Broad","year":"2013","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0205","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.otohns.2005.10.059","article-title":"Sinusitis of odontogenic origin","volume":"135","author":"Brook","year":"2006","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0210","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1136\/thoraxjnl-2012-202698","article-title":"Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial","volume":"68","author":"Brusselle","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0215","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1179\/joc.2010.22.5.291","article-title":"Antibiotic therapy for exacerbations of chronic obstructive pulmonary disease (COPD)","volume":"22","author":"Butorac-Petanjek","year":"2010","journal-title":"J Chemother"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0220","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1111\/j.1365-2222.2012.03979.x","article-title":"Long-term macrolide treatment of chronic inflammatory airway diseases: risks, benefits and future developments","volume":"42","author":"Cameron","year":"2012","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0225","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/BF01969103","article-title":"Comparative studies on the effects of erythromycin A and azithromycin upon extracellular release of lysosomal enzymes in inflammatory processes","volume":"25","author":"Carevic","year":"1988","journal-title":"Agents Actions"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0230","first-page":"211","article-title":"Accumulation, release and subcellular localization of azithromycin in phagocytic and non-phagocytic cells in culture","volume":"16","author":"Carlier","year":"1994","journal-title":"Int J Tissue React"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0235","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s002849900290","article-title":"Azithromycin and clarithromycin inhibition of 50S ribosomal subunit formation in Staphylococcus aureus cells","volume":"36","author":"Champney","year":"1998","journal-title":"Curr Microbiol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0240","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s002849900402","article-title":"A comparison of the inhibition of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells by nine different macrolide antibiotics","volume":"37","author":"Champney","year":"1998","journal-title":"Curr Microbiol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0245","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.bbrc.2006.09.132","article-title":"Anti-inflammatory effects of azithromycin in cystic fibrosis airway epithelial cells","volume":"350","author":"Cigana","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0250","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/thx.2005.057950","article-title":"Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial","volume":"61","author":"Clement","year":"2006","journal-title":"Thorax"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0255","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1007\/BF01975839","article-title":"An open study to compare the pharmacokinetics, safety and tolerability of a multiple-dose regimen of azithromycin in young and elderly volunteers","volume":"10","author":"Coates","year":"1991","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0260","doi-asserted-by":"crossref","first-page":"e72148","DOI":"10.1371\/journal.pone.0072148","article-title":"Drug-induced acute myocardial infarction: identifying \u2018prime suspects\u2019 from electronic healthcare records-based surveillance system","volume":"8","author":"Coloma","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0265","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0014-2999(02)02042-3","article-title":"Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects","volume":"450","author":"Culic","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0270","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0014-2999(01)01321-8","article-title":"Anti-inflammatory effects of macrolide antibiotics","volume":"429","author":"Culic","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0275","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1007\/s11095-011-0386-9","article-title":"Effects of food on a gastrically degraded drug: azithromycin fast-dissolving gelatin capsules and HPMC capsules","volume":"28","author":"Curatolo","year":"2011","journal-title":"Pharm Res"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0280","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ejphar.2006.09.041","article-title":"Azithromycin has a direct relaxant effect on precontracted airway smooth muscle","volume":"553","author":"Daenas","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0285","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1128\/AAC.00527-07","article-title":"Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast","volume":"51","author":"Dahl","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0290","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/CCM.0b013e31827e83af","article-title":"Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012","volume":"41","author":"Dellinger","year":"2013","journal-title":"Crit Care Med"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0295","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S1473-3099(13)70036-7","article-title":"Prevalence and resistance of commensal Staphylococcus aureus, including meticillin-resistant S. aureus, in nine European countries: a cross-sectional study","volume":"13","author":"den Heijer","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0300","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1043661802002384","article-title":"Pharmacokinetics of azithromycin in lung tissue, bronchial washing, and plasma in patients given multiple oral doses of 500 and 1000mg daily","volume":"46","author":"Di Paolo","year":"2002","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0305","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1093\/jac\/dkh469","article-title":"Emergence of invasive erythromycin-resistant Streptococcus pneumoniae strains in Portugal: contribution and phylogenetic relatedness of serotype 14","volume":"54","author":"Dias","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0310","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1124\/mol.59.6.1441","article-title":"Insights into the mechanism of azithromycin interaction with an Escherichia coli functional ribosomal complex","volume":"59","author":"Dinos","year":"2001","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0315","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.ijantimicag.2008.01.027","article-title":"Pharmacokinetics of azithromycin in serum and sinus fluid after administration of extended-release and immediate-release formulations in patients with acute bacterial sinusitis","volume":"31","author":"Ehnhage","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb9500","article-title":"Design of novel classes of macrolides for neutrophil dominated inflammatory diseases","volume":"6","author":"Erakovic Haber","year":"2014","journal-title":"Future Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0320","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1592\/phco.20.7.657.35176","article-title":"Comparison of the serum and intracellular pharmacokinetics of azithromycin in healthy and diabetic volunteers","volume":"20","author":"Ernst","year":"2000","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1450","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/01.inf.0000160949.99560.8d","article-title":"Role of atypical bacteria and azithromycin therapy for children with recurrent respiratory tract infections","volume":"24","author":"Esposito","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1455","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1016\/j.bbamem.2007.04.013","article-title":"Decrease of elastic moduli of DOPC bilayers induced by a macrolide antibiotic, azithromycin","volume":"1768","author":"Fa","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1460","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/sti.79.4.318","article-title":"Tetracycline treatment does not eradicate Mycoplasma genitalium","volume":"79","author":"Falk","year":"2003","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1465","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijantimicag.2009.01.014","article-title":"Pharmacokinetics of azithromycin in plasma and sinus mucosal tissue following administration of extended-release or immediate-release formulations in adult patients with chronic rhinosinusitis","volume":"34","author":"Fang","year":"2009","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2014.03.003_bb1470","doi-asserted-by":"crossref","first-page":"i17","DOI":"10.1093\/jac\/dkh312","article-title":"Distribution across the USA of macrolide resistance and macrolide resistance mechanisms among Streptococcus pneumoniae isolates collected from patients with respiratory tract infections: PROTEKT US 2001\u20132002","volume":"54","author":"Farrell","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1475","doi-asserted-by":"crossref","first-page":"E381","DOI":"10.1111\/j.1399-0012.2011.01435.x","article-title":"Clinical and immunological evaluation of 12-month azithromycin therapy in chronic lung allograft rejection","volume":"25","author":"Federica","year":"2011","journal-title":"Clin Transplant"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1480","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/jac\/45.2.191","article-title":"The Alexander Project 1996\u20131997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections","volume":"45","author":"Felmingham","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1485","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1128\/AAC.01424-09","article-title":"Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas","volume":"54","author":"Feola","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1490","first-page":"173","article-title":"Enhancement of human polymorphonuclear leucocyte motility by erythromycin in vitro and in vivo","volume":"66","author":"Fernandes","year":"1984","journal-title":"S Afr Med J"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1495","first-page":"153","article-title":"Azithromycin reduces inflammation in a rat model of acute conjunctivitis","volume":"19","author":"Fernandez-Robredo","year":"2013","journal-title":"Mol Vis"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1500","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1086\/425038","article-title":"Azithromycin modulates murine immune responses to pneumococcal conjugate vaccine and inhibits nasal clearance of bacteria","volume":"190","author":"Fernandez","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1505","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1007\/s00018-010-0284-z","article-title":"Regulation of autophagy in mammals and its interplay with apoptosis","volume":"67","author":"Fimia","year":"2010","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1510","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-002857","article-title":"Comparing two types of macrolide antibiotics for the purpose of assessing population-based drug interactions","volume":"3","author":"Fleet","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1515","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.tcb.2012.04.005","article-title":"Autophagy proteins in macroendocytic engulfment","volume":"22","author":"Florey","year":"2012","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1520","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1007\/BF01975845","article-title":"Concentration of azithromycin in human prostatic tissue","volume":"10","author":"Foulds","year":"1991","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"Suppl. A","key":"10.1016\/j.pharmthera.2014.03.003_bb1525","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/jac\/25.suppl_A.73","article-title":"The pharmacokinetics of azithromycin in human serum and tissues","volume":"25","author":"Foulds","year":"1990","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1530","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2174\/1568005043340740","article-title":"Macrolide resistance from the ribosome perspective","volume":"4","author":"Franceschi","year":"2004","journal-title":"Curr Drug Targets Infect Disord"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1535","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1124\/dmd.108.022285","article-title":"Involvement of intestinal uptake transporters in the absorption of azithromycin and clarithromycin in the rat","volume":"36","author":"Garver","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1540","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(11)61515-8","article-title":"Comparison of annual versus twice-yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster-randomised trial","volume":"379","author":"Gebre","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1545","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0014-5793(96)00975-1","article-title":"Hyperactivity of cathepsin B and other lysosomal enzymes in fibroblasts exposed to azithromycin, a dicationic macrolide antibiotic with exceptional tissue accumulation","volume":"394","author":"Gerbaux","year":"1996","journal-title":"FEBS Lett"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1550","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1164\/rccm.200212-1424BC","article-title":"Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study","volume":"168","author":"Gerhardt","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1555","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/j.1432-2277.2008.00670.x","article-title":"Azithromycin reduces airway inflammation in a murine model of lung ischaemia reperfusion injury","volume":"21","author":"Geudens","year":"2008","journal-title":"Transpl Int"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1560","article-title":"Effect of clarithromycin in patients with suspected Gram-negative sepsis: results of a randomized controlled trial","author":"Giamarellos-Bourboulis","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1565","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1086\/529439","article-title":"Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia","volume":"46","author":"Giamarellos-Bourboulis","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1570","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00005392-200101000-00024","article-title":"Pharmacokinetics of clarithromycin in the prostate: implications for the treatment of chronic abacterial prostatitis","volume":"165","author":"Giannopoulos","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0325","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1183\/09031936.00095809","article-title":"Azithromycin induces anti-viral responses in bronchial epithelial cells","volume":"36","author":"Gielen","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0330","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1128\/AAC.46.12.3750-3755.2002","article-title":"A novel efflux system in inducibly erythromycin-resistant strains of Streptococcus pyogenes","volume":"46","author":"Giovanetti","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0335","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1128\/AAC.43.8.1935","article-title":"Phenotypes and genotypes of erythromycin-resistant Streptococcus pyogenes strains in Italy and heterogeneity of inducibly resistant strains","volume":"43","author":"Giovanetti","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0340","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3949\/ccjm.80a.13077","article-title":"Azithromycin and risk of sudden cardiac death: guilty as charged or falsely accused?","volume":"80","author":"Giudicessi","year":"2013","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0345","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1128\/AAC.33.3.277","article-title":"In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection","volume":"33","author":"Gladue","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0350","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1128\/AAC.34.6.1056","article-title":"Intracellular accumulation of azithromycin by cultured human fibroblasts","volume":"34","author":"Gladue","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0355","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/j.intimp.2007.07.031","article-title":"The serum amyloid A response to sterile silver nitrate in mice and its inhibition by dexamethasone and macrolide antibiotics","volume":"7","author":"Glojnaric","year":"2007","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0360","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1902\/jop.2007.060246","article-title":"Drug concentration in inflamed periodontal tissues after systemically administered azithromycin","volume":"78","author":"Gomi","year":"2007","journal-title":"J Periodontol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0365","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/01.tp.0000295981.84633.bc","article-title":"Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation","volume":"85","author":"Gottlieb","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0370","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1165\/rcmb.2008-0357OC","article-title":"Azithromycin maintains airway epithelial integrity during Pseudomonas aeruginosa infection","volume":"42","author":"Halldorsson","year":"2010","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0375","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0924-8579(01)00430-7","article-title":"Characteristics and mechanisms of azithromycin accumulation and efflux in human polymorphonuclear leukocytes","volume":"18","author":"Hand","year":"2001","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0380","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1097-2765(02)00570-1","article-title":"The structures of four macrolide antibiotics bound to the large ribosomal subunit","volume":"10","author":"Hansen","year":"2002","journal-title":"Mol Cell"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0385","doi-asserted-by":"crossref","first-page":"e54981","DOI":"10.1371\/journal.pone.0054981","article-title":"The pharmacokinetic\u2013pharmacodynamic model of azithromycin for lipopolysaccharide-induced depressive-like behavior in mice","volume":"8","author":"Hao","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0390","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1177\/0091270010382021","article-title":"Pharmacokinetics, safety, and biologic effects of azithromycin in extremely preterm infants at risk for ureaplasma colonization and bronchopulmonary dysplasia","volume":"51","author":"Hassan","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0395","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1592\/phco.22.8.578.33217","article-title":"Effect of antibiotics on polymorphonuclear neutrophil apoptosis","volume":"22","author":"Healy","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0400","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1128\/AAC.47.9.2770-2774.2003","article-title":"Randomized double-blind study comparing 3- and 6-day regimens of azithromycin with a 10-day amoxicillin-clavulanate regimen for treatment of acute bacterial sinusitis","volume":"47","author":"Henry","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0405","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1600-0765.2011.01418.x","article-title":"Azithromycin in periodontal treatment: more than an antibiotic","volume":"47","author":"Hirsch","year":"2012","journal-title":"J Periodontal Res"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0410","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1183\/09031936.06.00001506","article-title":"Azithromycin increases phagocytosis of apoptotic bronchial epithelial cells by alveolar macrophages","volume":"28","author":"Hodge","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0415","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1164\/rccm.200711-1666OC","article-title":"Azithromycin improves macrophage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease","volume":"178","author":"Hodge","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0420","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1440-1843.2012.02135.x","article-title":"Low-dose azithromycin improves phagocytosis of bacteria by both alveolar and monocyte-derived macrophages in chronic obstructive pulmonary disease subjects","volume":"17","author":"Hodge","year":"2012","journal-title":"Respirology"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0425","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/BF01713565","article-title":"Pharmacokinetics of azithromycin in normal and impaired renal function","volume":"23","author":"Hoffler","year":"1995","journal-title":"Infection"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0430","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1128\/AAC.01011-06","article-title":"Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(\u2212\/\u2212) mice","volume":"51","author":"Hoffmann","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0435","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1741-7015-9-32","article-title":"Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis","volume":"9","author":"Hoiby","year":"2011","journal-title":"BMC Med"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0440","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0022-3565(24)35272-3","article-title":"Anti-inflammatory activity of macrolide antibiotics","volume":"292","author":"Ianaro","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0445","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.bbrc.2008.09.121","article-title":"Drug-induced phospholipidosis is caused by blockade of mannose 6-phosphate receptor-mediated targeting of lysosomal enzymes","volume":"377","author":"Ikeda","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0450","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1179\/joc.2009.21.4.396","article-title":"Azithromycin reduces tumor necrosis factor-alpha production in lipopolysaccharide-stimulated THP-1 monocytic cells by modification of stress response and p38 MAPK pathway","volume":"21","author":"Ikegaya","year":"2009","journal-title":"J Chemother"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0455","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1128\/AAC.48.9.3457-3461.2004","article-title":"Azithromycin inhibits MUC5AC production induced by the Pseudomonas aeruginosa autoinducer N-(3-Oxododecanoyl) homoserine lactone in NCI-H292 Cells","volume":"48","author":"Imamura","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0460","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1089\/mdr.2008.0806","article-title":"Antimicrobial susceptibility of respiratory tract pathogens in Japan during PROTEKT years 1\u20135 (1999\u20132004)","volume":"14","author":"Inoue","year":"2008","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0465","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ijantimicag.2004.03.022","article-title":"Macrolide antibiotics induce apoptosis of human peripheral lymphocytes in vitro","volume":"24","author":"Ishimatsu","year":"2004","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0470","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/jac\/dkn427","article-title":"Different effects of telithromycin on MUC5AC production induced by human neutrophil peptide-1 or lipopolysaccharide in NCI-H292 cells compared with azithromycin and clarithromycin","volume":"63","author":"Ishimoto","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0475","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ejphar.2006.03.074","article-title":"Anti-inflammatory activity of azithromycin attenuates the effects of lipopolysaccharide administration in mice","volume":"539","author":"Ivetic Tkalcevic","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0480","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s10753-011-9305-9","article-title":"Topical azithromycin and clarithromycin inhibit acute and chronic skin inflammation in sensitized mice, with apparent selectivity for Th2-mediated processes in delayed-type hypersensitivity","volume":"35","author":"Ivetic Tkalcevic","year":"2012","journal-title":"Inflammation"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0485","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/cei.12023","article-title":"Efficacy of azithromycin in preventing lethal graft-versus-host disease","volume":"171","author":"Iwamoto","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0490","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1365-2249.2011.04480.x","article-title":"The effect of azithromycin on the maturation and function of murine bone marrow-derived dendritic cells","volume":"166","author":"Iwamoto","year":"2011","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0495","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1097\/00006454-200308001-00004","article-title":"Macrolide resistance: an increasing concern for treatment failure in children","volume":"22","author":"Jacobs","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0500","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/01.inf.0000148927.48680.fc","article-title":"Pharmacokinetics of intravenously administered azithromycin in pediatric patients","volume":"24","author":"Jacobs","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0505","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-0711-7-1","article-title":"Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1\u20134","volume":"7","author":"Jenkins","year":"2008","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0510","doi-asserted-by":"crossref","first-page":"R38","DOI":"10.1093\/hmg\/ddq157","article-title":"Inclusion body myopathy, Paget's disease of the bone and fronto-temporal dementia: a disorder of autophagy","volume":"19","author":"Ju","year":"2010","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0515","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s004670000550","article-title":"Diffuse crescentic glomerulonephritis in bacterial endocarditis","volume":"16","author":"Kannan","year":"2001","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0520","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1128\/CMR.00078-09","article-title":"Mechanisms of action and clinical application of macrolides as immunomodulatory medications","volume":"23","author":"Kanoh","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0525","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/aas.12081","article-title":"Severe community-acquired pneumonia treated with beta-lactam-respiratory quinolone vs. beta-lactam-macrolide combination","volume":"57","author":"Karhu","year":"2013","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0530","first-page":"28","article-title":"The clinical and economic efficacies of short courses of azithromycin in acute sinusitis","volume":"44","author":"Karpov","year":"1999","journal-title":"Antibiot Khimioter"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0535","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1177\/089686080102100407","article-title":"Azithromycin: an assessment of its pharmacokinetics and therapeutic potential in CAPD","volume":"21","author":"Kent","year":"2001","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0540","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s10840-007-9124-y","article-title":"Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other known precipitating factors","volume":"18","author":"Kezerashvili","year":"2007","journal-title":"J Interv Card Electrophysiol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0545","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1183\/09031936.95.08091451","article-title":"Effect of erythromycin on Haemophilus influenzae endotoxin-induced release of IL-6, IL-8 and sICAM-1 by cultured human bronchial epithelial cells","volume":"8","author":"Khair","year":"1995","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0550","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0924-8579(98)00091-0","article-title":"Effect of clarithromycin and azithromycin on production of cytokines by human monocytes","volume":"11","author":"Khan","year":"1999","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0555","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000138716","article-title":"Enhanced interleukin production after long-term administration of erythromycin stearate","volume":"41","author":"Kita","year":"1990","journal-title":"Pharmacology"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0560","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/ppul.20748","article-title":"Azithromycin does not improve disease course in hospitalized infants with respiratory syncytial virus (RSV) lower respiratory tract disease: a randomized equivalence trial","volume":"43","author":"Kneyber","year":"2008","journal-title":"Pediatr Pulmonol"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2014.03.003_bb0565","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/0924-8579(93)90039-8","article-title":"Therapeutic possibilities for diffuse panbronchiolitis","volume":"3","author":"Kobayashi","year":"1993","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0570","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1124\/jpet.112.200733","article-title":"A novel macrolide solithromycin exerts superior anti-inflammatory effect via NF-kappaB inhibition","volume":"345","author":"Kobayashi","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0575","unstructured":"Kobrehel, G., Radobolja, G., Tamburasev, Z., Djokic, S. (1982). 11-Aza-10-deoxo-10-dihydroerythromycin A and derivatives thereof as well as a process for their preparation. U.S. Patent 4,328,334."},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0580","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/jac\/46.1.19","article-title":"Apoptosis, oxidative metabolism and interleukin-8 production in human neutrophils exposed to azithromycin: effects of Streptococcus pneumoniae","volume":"46","author":"Koch","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0585","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1128\/AAC.00613-07","article-title":"Ribosome protection prevents azithromycin-mediated quorum-sensing modulation and stationary-phase killing of Pseudomonas aeruginosa","volume":"51","author":"Kohler","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0590","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1179\/joc.2011.23.6.350","article-title":"A switch therapy protocol with intravenous azithromycin and ciprofloxacin combination for severe, relapsing chronic bacterial prostatitis: a prospective non-comparative pilot study","volume":"23","author":"Kolumbic Lakos","year":"2011","journal-title":"J Chemother"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0595","doi-asserted-by":"crossref","first-page":"L107","DOI":"10.1016\/0024-3205(92)90493-9","article-title":"Influences of roxithromycin on cell-mediated immune responses","volume":"51","author":"Konno","year":"1992","journal-title":"Life Sci"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0600","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev.bi.61.070192.001515","article-title":"Structure and function of the mannose 6-phosphate\/insulinlike growth factor II receptors","volume":"61","author":"Kornfeld","year":"1992","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0605","doi-asserted-by":"crossref","first-page":"5632","DOI":"10.1021\/jm300647f","article-title":"Probing the interactions of macrolide antibiotics with membrane-mimetics by NMR spectroscopy","volume":"55","author":"Kosol","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0610","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1517\/14728214.2012.697151","article-title":"Emerging drugs for the treatment of sepsis","volume":"17","author":"Kotsaki","year":"2012","journal-title":"Expert Opin Emerg Drugs"},{"issue":"Suppl. 9A","key":"10.1016\/j.pharmthera.2014.03.003_bb0615","first-page":"12S","article-title":"Applying lessons learned in the treatment of diffuse panbronchiolitis to other chronic inflammatory diseases","volume":"117","author":"Kudoh","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0620","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1164\/ajrccm.157.6.9710075","article-title":"Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin","volume":"157","author":"Kudoh","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0625","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1185\/03007995.2011.639355","article-title":"Safety and effectiveness of azithromycin in the treatment of respiratory infections in children","volume":"28","author":"Lakos","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0630","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/00007435-200209000-00001","article-title":"Azithromycin versus doxycycline for genital chlamydial infections: a meta-analysis of randomized clinical trials","volume":"29","author":"Lau","year":"2002","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0635","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1086\/324626","article-title":"Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications","volume":"34","author":"Leclercq","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0640","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/1465-9921-7-134","article-title":"Azithromycin reduces spontaneous and induced inflammation in DeltaF508 cystic fibrosis mice","volume":"7","author":"Legssyer","year":"2006","journal-title":"Respir Res"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0645","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1128\/AAC.02067-13","article-title":"Adverse effects of long-term azithromycin use in patients with chronic lung diseases: a meta-analysis","volume":"58","author":"Li","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0650","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2169\/internalmedicine.50.4727","article-title":"Effect of azithromycin on patients with diffuse panbronchiolitis: retrospective study of 51 cases","volume":"50","author":"Li","year":"2011","journal-title":"Intern Med"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0655","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1053\/rmed.1999.0781","article-title":"Erythromycin inhibits beta2-integrins (CD11b\/CD18) expression, interleukin-8 release and intracellular oxidative metabolism in neutrophils","volume":"94","author":"Lin","year":"2000","journal-title":"Respir Med"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0660","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.intimp.2012.02.013","article-title":"Effect of azithromycin on natural killer cell function","volume":"13","author":"Lin","year":"2012","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0665","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.1128\/AAC.00692-11","article-title":"Comparison of azithromycin pharmacokinetics following single oral doses of extended-release and immediate-release formulations in children with acute otitis media","volume":"55","author":"Liu","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. C","key":"10.1016\/j.pharmthera.2014.03.003_bb0670","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/37.suppl_C.1","article-title":"Azithromycin\u2014review of key chemical, pharmacokinetic and microbiological features","volume":"37","author":"Lode","year":"1996","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0675","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1093\/jac\/dkn032","article-title":"Pharmacokinetics of azithromycin in serum, bronchial washings, alveolar macrophages and lung tissue following a single oral dose of extended or immediate release formulations of azithromycin","volume":"61","author":"Lucchi","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0680","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2147\/OPTH.S6370","article-title":"Azithromycin in DuraSite for the treatment of blepharitis","volume":"4","author":"Luchs","year":"2010","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0685","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0009-9236(97)90098-9","article-title":"Disposition of oral azithromycin in humans","volume":"61","author":"Luke","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0690","first-page":"689","article-title":"Inhibition of airway mucous hypersecretion by azithromycin through matrix metalloproteinase 9","volume":"91","author":"Luo","year":"2011","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0695","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/1471-2180-12-196","article-title":"Macrolides decrease the minimal inhibitory concentration of anti-pseudomonal agents against Pseudomonas aeruginosa from cystic fibrosis patients in biofilm","volume":"12","author":"Lutz","year":"2012","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0700","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1439-0272.2009.01033.x","article-title":"Eradication of Chlamydia trachomatis parallels symptom regression in chronic bacterial prostatitis patients treated with a fluoroquinolone-macrolide combination","volume":"42","author":"Magri","year":"2010","journal-title":"Andrologia"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0705","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ijantimicag.2006.09.027","article-title":"Efficacy of repeated cycles of combination therapy for the eradication of infecting organisms in chronic bacterial prostatitis","volume":"29","author":"Magri","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0710","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S0140-6736(07)60235-9","article-title":"Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study","volume":"369","author":"Malhotra-Kumar","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0715","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/ajim.20196","article-title":"World Trade Center dyspnea: bronchiolitis obliterans with functional improvement: a case report","volume":"48","author":"Mann","year":"2005","journal-title":"Am J Ind Med"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0720","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.phrs.2011.02.001","article-title":"Macrolide antibiotics broadly and distinctively inhibit cytokine and chemokine production by COPD sputum cells in vitro","volume":"63","author":"Marjanovic","year":"2011","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0725","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amjoto.2008.08.011","article-title":"Azithromycin extended release vs amoxicillin\/clavulanate: symptom resolution in acute sinusitis","volume":"31","author":"Marple","year":"2010","journal-title":"Am J Otolaryngol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0730","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1007\/s00134-009-1730-y","article-title":"Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia","volume":"36","author":"Martin-Loeches","year":"2010","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0735","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.idc.2005.06.001","article-title":"The expanded spectrum of bartonellosis in children","volume":"19","author":"Massei","year":"2005","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0740","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.phrs.2012.06.001","article-title":"Fluorescently labeled macrolides as a tool for monitoring cellular and tissue distribution of azithromycin","volume":"66","author":"Matijasic","year":"2012","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0745","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1902\/jop.2011.100721","article-title":"Azithromycin may inhibit interleukin-8 through suppression of Rac1 and a nuclear factor-kappa B pathway in KB cells stimulated with lipopolysaccharide","volume":"82","author":"Matsumura","year":"2011","journal-title":"J Periodontol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0750","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1128\/AAC.02011-12","article-title":"Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy","volume":"57","author":"Matzneller","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. E","key":"10.1016\/j.pharmthera.2014.03.003_bb0755","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/jac\/31.suppl_E.57","article-title":"Pharmacokinetics of azithromycin in patients with impaired hepatic function","volume":"31","author":"Mazzei","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0760","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1007\/BF01975835","article-title":"Phagocyte uptake and transport of azithromycin","volume":"10","author":"McDonald","year":"1991","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0765","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1086\/599033","article-title":"A randomized comparison of azithromycin and doxycycline for the treatment of Mycoplasma genitalium-positive urethritis in men","volume":"48","author":"Mena","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0770","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejphar.2011.04.036","article-title":"Development of non-antibiotic macrolide that corrects inflammation-driven immune dysfunction in models of inflammatory bowel diseases and arthritis","volume":"665","author":"Mencarelli","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0775","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.clinthera.2013.02.012","article-title":"Effect of azithromycin on anticoagulation-related outcomes in geriatric patients receiving warfarin","volume":"35","author":"Mergenhagen","year":"2013","journal-title":"Clin Ther"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0780","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1007\/s10620-009-0725-4","article-title":"Azithromycin reduces gastroesophageal reflux and aspiration in lung transplant recipients","volume":"54","author":"Mertens","year":"2009","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0785","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1378\/chest.06-1426","article-title":"Antibiotics for bacteremic pneumonia: improved outcomes with macrolides but not fluoroquinolones","volume":"131","author":"Metersky","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0790","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1165\/rcmb.2008-0155OC","article-title":"Azithromycin reduces exaggerated cytokine production by M1 alveolar macrophages in cystic fibrosis","volume":"41","author":"Meyer","year":"2009","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0795","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1124\/jpet.102.037911","article-title":"Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes","volume":"303","author":"Milberg","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0800","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1006\/jsre.2000.5847","article-title":"Chlamydia pneumoniae activates nuclear factor kappaB and activator protein 1 in human vascular smooth muscle and induces cellular proliferation","volume":"90","author":"Miller","year":"2000","journal-title":"J Surg Res"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0805","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00204-008-0388-5","article-title":"Effects of macrolides on proinflammatory epitopes on endothelial cells in vitro","volume":"83","author":"Millrose","year":"2009","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0810","doi-asserted-by":"crossref","first-page":"649570","DOI":"10.1155\/2012\/649570","article-title":"Macrolide therapy in respiratory viral infections","volume":"2012","author":"Min","year":"2012","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0815","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1128\/AAC.43.10.2457","article-title":"The new ketolide HMR3647 accumulates in the azurophil granules of human polymorphonuclear cells","volume":"43","author":"Miossec-Bartoli","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0820","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0952-3278(03)00089-9","article-title":"Macrolide antibiotics inhibit prostaglandin E2 synthesis and mRNA expression of prostaglandin synthetic enzymes in human leukocytes","volume":"69","author":"Miyazaki","year":"2003","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0825","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.intimp.2004.05.011","article-title":"Clarithromycin and azithromycin induce apoptosis of activated lymphocytes via down-regulation of Bcl-xL","volume":"4","author":"Mizunoe","year":"2004","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0830","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1006\/taap.1999.8632","article-title":"Interactions of macrolide antibiotics (Erythromycin A, roxithromycin, erythromycylamine [Dirithromycin], and azithromycin) with phospholipids: computer-aided conformational analysis and studies on acellular and cell culture models","volume":"156","author":"Montenez","year":"1999","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0835","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0014-2999(96)00553-5","article-title":"Interaction of the macrolide azithromycin with phospholipids. II. Biophysical and computer-aided conformational studies","volume":"314","author":"Montenez","year":"1996","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0840","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.pupt.2009.08.004","article-title":"Azithromycin, clarithromycin and telithromycin inhibit MUC5AC induction by Chlamydophila pneumoniae in airway epithelial cells","volume":"22","author":"Morinaga","year":"2009","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0845","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.3892\/ijo.2013.1870","article-title":"Macrolide antibiotics block autophagy flux and sensitize to bortezomib via endoplasmic reticulum stress-mediated CHOP induction in myeloma cells","volume":"42","author":"Moriya","year":"2013","journal-title":"Int J Oncol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0850","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1128\/AAC.39.8.1676","article-title":"Role of extracellular calcium in in vitro uptake and intraphagocytic location of macrolides","volume":"39","author":"Mtairag","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0855","first-page":"CD004875","article-title":"Antibiotics for community-acquired lower respiratory tract infections secondary to Mycoplasma pneumoniae in children","volume":"9","author":"Mulholland","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0860","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.phrs.2011.03.011","article-title":"Intensity of macrolide anti-inflammatory activity in J774A.1 cells positively correlates with cellular accumulation and phospholipidosis","volume":"64","author":"Munic","year":"2011","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0865","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ejps.2010.05.016","article-title":"Differences in assessment of macrolide interaction with human MDR1 (ABCB1, P-gp) using rhodamine-123 efflux, ATPase activity and cellular accumulation assays","volume":"41","author":"Munic","year":"2010","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0870","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1093\/jac\/dkn007","article-title":"Azithromycin alters macrophage phenotype","volume":"61","author":"Murphy","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0875","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.healun.2008.07.026","article-title":"Azithromycin attenuates effects of lipopolysaccharide on lung allograft bronchial epithelial cells","volume":"27","author":"Murphy","year":"2008","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0880","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.otohns.2005.04.020","article-title":"Efficacy and safety of a novel, single-dose azithromycin microsphere formulation versus 10days of levofloxacin for the treatment of acute bacterial sinusitis in adults","volume":"133","author":"Murray","year":"2005","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0885","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/jac\/dkq398","article-title":"Pharmacokinetic\u2013pharmacodynamic analysis of azithromycin extended release in Japanese patients with common respiratory tract infectious disease","volume":"66","author":"Muto","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0890","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.04.2009.1780","article-title":"Not every cough in bronchiolitis season is bronchiolitis","volume":"2009","author":"Naidoo","year":"2009","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0895","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.4049\/jimmunol.0902866","article-title":"A new strategy for the identification of novel molecules with targeted proresolution of inflammation properties","volume":"184","author":"Navarro-Xavier","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0900","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ejphar.2012.06.040","article-title":"Naringin attenuates EGF-induced MUC5AC secretion in A549 cells by suppressing the cooperative activities of MAPKs-AP-1 and IKKs-IkappaB-NF-kappaB signaling pathways","volume":"690","author":"Nie","year":"2012","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0905","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/00006454-199704000-00027","article-title":"Pharmacokinetics and pharmacodynamics of newer macrolides","volume":"16","author":"Nightingale","year":"1997","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0910","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.cellimm.2012.09.007","article-title":"Impairment of lysosomal functions by azithromycin and chloroquine contributes to anti-inflammatory phenotype","volume":"279","author":"Nujic","year":"2012","journal-title":"Cell Immunol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0915","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ejphar.2011.12.022","article-title":"Valosin containing protein (VCP) interacts with macrolide antibiotics without mediating their anti-inflammatory activities","volume":"677","author":"Nujic","year":"2012","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0920","first-page":"CD001954","article-title":"Azithromycin for acute lower respiratory tract infections","author":"Panpanich","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0925","series-title":"Antibiotics as Anti-Inflammatory and Immunomodulatory Agents","first-page":"27","article-title":"Antibiotics, inflammation and its resolution: an overview","author":"Parnham","year":"2005"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0930","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejphar.2005.05.023","article-title":"Modulation of neutrophil and inflammation markers in chronic obstructive pulmonary disease by short-term azithromycin treatment","volume":"517","author":"Parnham","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0935","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/jac\/35.1.85","article-title":"Factors affecting the intracellular accumulation and activity of azithromycin","volume":"35","author":"Pascual","year":"1995","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0940","first-page":"G470","article-title":"Erythromycin is a motilin receptor agonist","volume":"257","author":"Peeters","year":"1989","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0945","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1128\/AAC.02430-12","article-title":"Development of a population pharmacokinetic model to describe azithromycin whole-blood and plasma concentrations over time in healthy subjects","volume":"57","author":"Pene Dumitrescu","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0950","first-page":"1035","article-title":"Macrolides for the treatment of chronic bacterial prostatitis: an effective application of their unique pharmacokinetic and pharmacodynamic profile (Review)","volume":"4","author":"Perletti","year":"2011","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0955","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1465-9921-13-83","article-title":"Leaky lysosomes in lung transplant macrophages: azithromycin prevents oxidative damage","volume":"13","author":"Persson","year":"2012","journal-title":"Respir Res"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0960","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2500\/aap.2007.28.2958","article-title":"Azithromycin reduces bronchial hyperresponsiveness and neutrophilic airway inflammation in asthmatic children: a preliminary report","volume":"28","author":"Piacentini","year":"2007","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0965","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.jpeds.2012.05.053","article-title":"Azithromycin therapy in hospitalized infants with acute bronchiolitis is not associated with better clinical outcomes: a randomized, double-blinded, and placebo-controlled clinical trial","volume":"161","author":"Pinto","year":"2012","journal-title":"J Pediatr"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0970","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ijantimicag.2007.04.015","article-title":"Single-dose azithromycin versus erythromycin or amoxicillin for Chlamydia trachomatis infection during pregnancy: a meta-analysis of randomised controlled trials","volume":"30","author":"Pitsouni","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0975","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1007\/s10620-009-1034-7","article-title":"Effect of azithromycin on acute inflammatory lesions and colonic bacterial load in a murine model of experimental colitis","volume":"55","author":"Plesko","year":"2010","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0980","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1189\/jlb.1210655","article-title":"Azithromycin drives in vitro GM-CSF\/IL-4-induced differentiation of human blood monocytes toward dendritic-like cells with regulatory properties","volume":"91","author":"Polancec","year":"2012","journal-title":"J Leukoc Biol"},{"issue":"Suppl. C","key":"10.1016\/j.pharmthera.2014.03.003_bb0985","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/jac\/37.suppl_C.53","article-title":"Penetration of azithromycin into middle ear effusions in acute and secretory otitis media in children","volume":"37","author":"Pukander","year":"1996","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0990","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/00007691-199812000-00018","article-title":"Simultaneous high-performance liquid chromatography analysis of azithromycin and two of its metabolites in human tears and plasma","volume":"20","author":"Raines","year":"1998","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb0995","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1067\/mob.2003.141","article-title":"Maternal and transplacental pharmacokinetics of azithromycin","volume":"188","author":"Ramsey","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1000","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.it.2012.06.003","article-title":"Autophagy in the regulation of pathogen replication and adaptive immunity","volume":"33","author":"Randow","year":"2012","journal-title":"Trends Immunol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1005","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1056\/NEJMoa1003833","article-title":"Azithromycin and the risk of cardiovascular death","volume":"366","author":"Ray","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1010","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1172\/JCI46095","article-title":"Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection","volume":"121","author":"Renna","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1015","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1183\/09031936.00054108","article-title":"Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia","volume":"33","author":"Restrepo","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1020","doi-asserted-by":"crossref","first-page":"e5806","DOI":"10.1371\/journal.pone.0005806","article-title":"Azithromycin treatment alters gene expression in inflammatory, lipid metabolism, and cell cycle pathways in well-differentiated human airway epithelia","volume":"4","author":"Ribeiro","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1025","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1128\/AAC.47.8.2450-2457.2003","article-title":"Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults","volume":"47","author":"Rodvold","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1030","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1136\/gutjnl-2011-300926","article-title":"Effect of azithromycin on acid reflux, hiatus hernia and proximal acid pocket in the postprandial period","volume":"61","author":"Rohof","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1035","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/jama.2010.563","article-title":"Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial","volume":"303","author":"Saiman","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1040","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jama.290.13.1749","article-title":"Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial","volume":"290","author":"Saiman","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2011.10.027","article-title":"Azithromycin fails to reduce inflammation in cystic fibrosis airway epithelial cells","volume":"674","author":"Saint-Criq","year":"2012","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1050","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000196514","article-title":"Interleukin 1 beta, tumor necrosis factor alpha, and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy","volume":"63","author":"Sakito","year":"1996","journal-title":"Respiration"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1055","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1128\/AAC.00771-09","article-title":"Pharmacokinetic properties of azithromycin in pregnancy","volume":"54","author":"Salman","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1060","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.plefa.2006.12.005","article-title":"Macrolide antibiotics promote the LPS-induced upregulation of prostaglandin E receptor EP2 and thus attenuate macrolide suppression of IL-6 production","volume":"76","author":"Sato","year":"2007","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1065","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1046\/j.1365-2125.1999.00887.x","article-title":"Interpretation of middle ear fluid concentrations of antibiotics: comparison between ceftibuten, cefixime and azithromycin","volume":"47","author":"Scaglione","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1070","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.rmed.2011.01.009","article-title":"Long-term, low-dose erythromycin in bronchiectasis subjects with frequent infective exacerbations","volume":"105","author":"Serisier","year":"2011","journal-title":"Respir Med"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1075","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1517\/14656566.7.6.639","article-title":"Drug interactions during therapy with three major groups of antimicrobial agents","volume":"7","author":"Shakeri-Nejad","year":"2006","journal-title":"Expert Opin Pharmacother"},{"issue":"Suppl. A","key":"10.1016\/j.pharmthera.2014.03.003_bb1080","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/jac\/25.suppl_A.49","article-title":"Pharmacokinetics of azithromycin in rats and dogs","volume":"25","author":"Shepard","year":"1990","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1085","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.pharmthera.2007.11.001","article-title":"Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action","volume":"117","author":"Shinkai","year":"2008","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1090","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1128\/AAC.50.5.1738-1744.2006","article-title":"Clarithromycin delays progression of bronchial epithelial cells from G1 phase to S phase and delays cell growth via extracellular signal-regulated protein kinase suppression","volume":"50","author":"Shinkai","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1095","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-002898","article-title":"Azithromycin and survival in Streptococcus pneumoniae pneumonia: a retrospective study","volume":"3","author":"Shorr","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1100","first-page":"505","article-title":"Clinical pharmacokinetics of azithromycin","volume":"43","author":"Singlas","year":"1995","journal-title":"Pathol Biol (Paris)"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1105","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1469-0691.2012.03838.x","article-title":"Macrolides vs. quinolones for community-acquired pneumonia: meta-analysis of randomized controlled trials","volume":"19","author":"Skalsky","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1110","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ijantimicag.2004.03.014","article-title":"Comparative randomized pilot study of azithromycin and doxycycline efficacy in the treatment of prostate infection caused by Chlamydia trachomatis","volume":"24","author":"Skerk","year":"2004","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1115","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000090234","article-title":"Comparative randomized pilot study of azithromycin and doxycycline efficacy and tolerability in the treatment of prostate infection caused by Ureaplasma urealyticum","volume":"52","author":"Skerk","year":"2006","journal-title":"Chemotherapy"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1120","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0924-8579(03)00056-6","article-title":"Comparative analysis of azithromycin and ciprofloxacin in the treatment of chronic prostatitis caused by Chlamydia trachomatis","volume":"21","author":"Skerk","year":"2003","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1125","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1179\/joc.2002.14.4.384","article-title":"Comparative analysis of azithromycin and clarithromycin efficacy and tolerability in the treatment of chronic prostatitis caused by Chlamydia trachomatis","volume":"14","author":"Skerk","year":"2002","journal-title":"J Chemother"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1130","first-page":"CD002203","article-title":"Macrolide antibiotics for cystic fibrosis","author":"Southern","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1135","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1183\/09031936.00136712","article-title":"Long-term macrolide treatment for chronic respiratory disease","volume":"42","author":"Spagnolo","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1140","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1128\/AAC.05798-11","article-title":"Effect of clarithromycin in inflammatory markers of patients with ventilator-associated pneumonia and sepsis caused by Gram-negative bacteria: results from a randomized clinical study","volume":"56","author":"Spyridaki","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1145","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1089\/dna.2010.1167","article-title":"Azithromycin treatment modulates the extracellular signal-regulated kinase mediated pathway and inhibits inflammatory cytokines and chemokines in epithelial cells from infertile women with recurrent Chlamydia trachomatis infection","volume":"30","author":"Srivastava","year":"2011","journal-title":"DNA Cell Biol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1150","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/ja.2009.125","article-title":"Azithromycin reduces the viability of human bronchial smooth muscle cells","volume":"63","author":"Stamatiou","year":"2010","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1155","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1183\/09031936.00089407","article-title":"Azithromycin has an antiproliferative and autophagic effect on airway smooth muscle cells","volume":"34","author":"Stamatiou","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1160","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1001\/jama.1995.03530070043027","article-title":"Azithromycin for empirical treatment of the nongonococcal urethritis syndrome in men. A randomized double-blind study","volume":"274","author":"Stamm","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1165","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1021\/jm101317f","article-title":"Modeling cellular pharmacokinetics of 14- and 15-membered macrolides with physicochemical properties","volume":"54","author":"Stepanic","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1170","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1378\/chest.128.5.3611","article-title":"Macrolides: a treatment alternative for bronchiolitis obliterans organizing pneumonia?","volume":"128","author":"Stover","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1175","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1128\/AAC.48.3.809-814.2004","article-title":"Possible involvement of the drug transporters P glycoprotein and multidrug resistance-associated protein Mrp2 in disposition of azithromycin","volume":"48","author":"Sugie","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1180","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1365-2249.2007.03299.x","article-title":"Differing effects of clarithromycin and azithromycin on cytokine production by murine dendritic cells","volume":"147","author":"Sugiyama","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1185","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.rmed.2013.02.009","article-title":"Role of long term antibiotics in chronic respiratory diseases","volume":"107","author":"Suresh Babu","year":"2013","journal-title":"Respir Med"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1190","series-title":"Macrolide Antibiotics","first-page":"281","article-title":"Mechanisms of resistance to macrolides, lincosamides, and ketolides","author":"Sutcliffe","year":"2002"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1195","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1056\/NEJMoa1300799","article-title":"Use of azithromycin and death from cardiovascular causes","volume":"368","author":"Svanstrom","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1200","first-page":"1625","article-title":"Ocular levels of azithromycin","volume":"116","author":"Tabbara","year":"1998"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1205","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1128\/AAC.44.8.2118-2125.2000","article-title":"Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage","volume":"44","author":"Tait-Kamradt","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. 9A","key":"10.1016\/j.pharmthera.2014.03.003_bb1210","first-page":"5S","article-title":"Clinical implications of the immunomodulatory effects of macrolides","volume":"117","author":"Tamaoki","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1215","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1128\/AAC.45.6.1930-1933.2001","article-title":"Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa","volume":"45","author":"Tateda","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1220","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/09629350310001599620","article-title":"Suppressive activity of macrolide antibiotics on nitric oxide production by lipopolysaccharide stimulation in mice","volume":"12","author":"Terao","year":"2003","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1225","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/jac\/dkp088","article-title":"Impact of intravenous {beta}-lactam\/macrolide versus {beta}-lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia","volume":"63","author":"Tessmer","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1230","first-page":"93","article-title":"Chlamydial cervicitis and urethritis: single dose treatment compared with doxycycline for seven days in community based practises","volume":"72","author":"Thorpe","year":"1996","journal-title":"Genitourin Med"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1235","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.bmc.2012.10.036","article-title":"Macrolactonolides: a novel class of anti-inflammatory compounds","volume":"21","author":"Tomaskovic","year":"2013","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1240","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1128\/AAC.37.9.1786","article-title":"In vivo administration of azithromycin affects lymphocyte activity in vitro","volume":"37","author":"Tomazic","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1245","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.imlet.2011.04.001","article-title":"Azithromycin acts as an immunomodulatory agent to suppress the expression of TREM-1 in Bacillus pyocyaneus-induced sepsis","volume":"138","author":"Tong","year":"2011","journal-title":"Immunol Lett"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1250","doi-asserted-by":"crossref","first-page":"217","DOI":"10.4161\/auto.6.2.11014","article-title":"VCP\/p97 is essential for maturation of ubiquitin-containing autophagosomes and this function is impaired by mutations that cause IBMPFD","volume":"6","author":"Tresse","year":"2010","journal-title":"Autophagy"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1255","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00011-009-0015-9","article-title":"Azithromycin increases survival and reduces lung inflammation in cystic fibrosis mice","volume":"58","author":"Tsai","year":"2009","journal-title":"Inflamm Res"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1260","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1164\/rccm.200402-200OC","article-title":"Azithromycin blocks neutrophil recruitment in Pseudomonas endobronchial infection","volume":"170","author":"Tsai","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1265","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.2174\/1381612043383430","article-title":"Immunomodulatory effects of macrolides in the lung: lessons from in-vitro and in-vivo models","volume":"10","author":"Tsai","year":"2004","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1270","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00232-002-1076-7","article-title":"The macrolide antibiotic azithromycin interacts with lipids and affects membrane organization and fluidity: studies on Langmuir\u2013Blodgett monolayers, liposomes and J774 macrophages","volume":"192","author":"Tyteca","year":"2003","journal-title":"J Membr Biol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1275","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1006\/excr.2002.5613","article-title":"Azithromycin, a lysosomotropic antibiotic, has distinct effects on fluid-phase and receptor-mediated endocytosis, but does not impair phagocytosis in J774 macrophages","volume":"281","author":"Tyteca","year":"2002","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1280","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1078\/0171-9335-00180","article-title":"Azithromycin, a lysosomotropic antibiotic, impairs fluid-phase pinocytosis in cultured fibroblasts","volume":"80","author":"Tyteca","year":"2001","journal-title":"Eur J Cell Biol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1285","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S2213-2600(13)70185-1","article-title":"Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial","volume":"1","author":"Valery","year":"2013","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1290","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0014-2999(96)00552-3","article-title":"Interaction of the macrolide azithromycin with phospholipids. I. Inhibition of lysosomal phospholipase A1 activity","volume":"314","author":"Van Bambeke","year":"1996","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1295","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1007\/s00134-012-2559-3","article-title":"Azithromycin to prevent Pseudomonas aeruginosa ventilator-associated pneumonia by inhibition of quorum sensing: a randomized controlled trial","volume":"38","author":"van Delden","year":"2012","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1300","first-page":"CD006688","article-title":"Azithromycin for treating uncomplicated malaria","author":"van Eijk","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1305","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1183\/09031936.00134307","article-title":"A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy","volume":"32","author":"Vanaudenaerde","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1310","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2174\/187152808786848414","article-title":"Macrolide therapy targets a specific phenotype in respiratory medicine: from clinical experience to basic science and back","volume":"7","author":"Vanaudenaerde","year":"2008","journal-title":"Inflamm Allergy Drug Targets"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1315","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1600-6143.2006.01586.x","article-title":"Macrolides inhibit IL17-induced IL8 and 8-isoprostane release from human airway smooth muscle cells","volume":"7","author":"Vanaudenaerde","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1320","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1164\/rccm.200601-071OC","article-title":"Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome","volume":"174","author":"Verleden","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1325","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.trim.2011.06.006","article-title":"Azithromycin decreases MMP-9 expression in the airways of lung transplant recipients","volume":"25","author":"Verleden","year":"2011","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1330","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.healun.2010.12.008","article-title":"Heterogeneity of chronic lung allograft dysfunction: insights from protein expression in broncho alveolar lavage","volume":"30","author":"Verleden","year":"2011","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1335","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1111\/j.1398-9995.2011.02693.x","article-title":"Lack of efficacy of long-term, low-dose azithromycin in chronic rhinosinusitis: a randomized controlled trial","volume":"66","author":"Videler","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jvp.12010","article-title":"Pharmacokinetics of macrolides in foals","volume":"36","author":"Villarino","year":"2013","journal-title":"J Vet Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1345","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.healun.2010.05.023","article-title":"Long-term azithromycin therapy for bronchiolitis obliterans syndrome: divide and conquer?","volume":"29","author":"Vos","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1350","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1183\/09031936.00068310","article-title":"A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation","volume":"37","author":"Vos","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1355","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1111\/j.1476-5381.2011.01576.x","article-title":"Azithromycin distinctively modulates classical activation of human monocytes in vitro","volume":"165","author":"Vrancic","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1360","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1440-1681.2000.03308.x","article-title":"Reversal of anticancer drug resistance by macrolide antibiotics in vitro and in vivo","volume":"27","author":"Wang","year":"2000","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1365","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1254\/jphs.09R25FM","article-title":"Roles of oral bacteria in cardiovascular diseases\u2014from molecular mechanisms to clinical cases: treatment of periodontal disease regarded as biofilm infection: systemic administration of azithromycin","volume":"113","author":"Wang","year":"2010","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1370","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11882-006-0056-x","article-title":"The use of macrolides in treatment of upper respiratory tract infections","volume":"6","author":"Wierzbowski","year":"2006","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1375","first-page":"484","article-title":"Uptake and subcellular distribution of azithromycin in human phagocytic cells. Demonstration of the antibiotic in neutrophil polymorphonuclear leucocytes and monocytes by autoradiography and electron microscopy","volume":"43","author":"Wildfeuer","year":"1993","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1380","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s12013-011-9331-0","article-title":"Azithromycin attenuates fibroblast growth factors induced vascular endothelial growth factor via p38(MAPK) signaling in human airway smooth muscle cells","volume":"67","author":"Willems-Widyastuti","year":"2013","journal-title":"Cell Biochem Biophys"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1385","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1194\/jlr.M500131-JLR200","article-title":"Mannose 6-phosphate receptors, Niemann-Pick C2 protein, and lysosomal cholesterol accumulation","volume":"46","author":"Willenborg","year":"2005","journal-title":"J Lipid Res"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1390","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/01.ftd.0000195617.69721.a5","article-title":"Pharmacokinetics of azithromycin in plasma, blood, polymorphonuclear neutrophils and sputum during long-term therapy in patients with cystic fibrosis","volume":"28","author":"Wilms","year":"2006","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1395","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1097\/CCM.0b013e31825151a8","article-title":"Comparison of two guideline-concordant antimicrobial combinations in elderly patients hospitalized with severe community-acquired pneumonia","volume":"40","author":"Wilson","year":"2012","journal-title":"Crit Care Med"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1400","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(12)60953-2","article-title":"Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial","volume":"380","author":"Wong","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1405","doi-asserted-by":"crossref","first-page":"602","DOI":"10.3109\/01902148.2010.492895","article-title":"Azithromycin reduces pulmonary fibrosis in a bleomycin mouse model","volume":"36","author":"Wuyts","year":"2010","journal-title":"Exp Lung Res"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1410","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1128\/AAC.00457-13","article-title":"Azithromycin attenuates lung inflammation in a mouse model of ventilator-associated pneumonia by multidrug-resistant Acinetobacter baumannii","volume":"57","author":"Yamada","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1415","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.abb.2010.11.004","article-title":"Sphingosylphosphorylcholine and lysosulfatide have inverse regulatory functions in monocytic cell differentiation into macrophages","volume":"506","author":"Yamamoto","year":"2011","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1420","doi-asserted-by":"crossref","first-page":"667","DOI":"10.7150\/ijbs.5.667","article-title":"Azithromycin suppresses interleukin-12p40 expression in lipopolysaccharide and interferon-gamma stimulated macrophages","volume":"5","author":"Yamauchi","year":"2009","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1425","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1183\/09031936.00208011","article-title":"Macrolide effects on the prevention of COPD exacerbations","volume":"40","author":"Yamaya","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1430","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2169\/internalmedicine.48.1482","article-title":"Efficacy of azithromycin in the treatment of community-acquired pneumonia, including patients with macrolide-resistant Streptococcus pneumoniae infection","volume":"48","author":"Yanagihara","year":"2009","journal-title":"Intern Med"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1435","first-page":"CD007716","article-title":"Macrolides for diffuse panbronchiolitis","volume":"2","author":"Yang","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1440","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1124\/jpet.102.037549","article-title":"Interaction of cytochrome P450 3A inhibitors with P-glycoprotein","volume":"303","author":"Yasuda","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2014.03.003_bb1445","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1600-065X.2007.00546.x","article-title":"Lipid signaling and the modulation of surface charge during phagocytosis","volume":"219","author":"Yeung","year":"2007","journal-title":"Immunol Rev"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725814000552?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725814000552?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:51:24Z","timestamp":1759009884000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725814000552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":315,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S0163725814000552"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2014.03.003","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Azithromycin: Mechanisms of action and their relevance for clinical applications","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2014.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}